Possible cause-effect relation between estrogen and focal nodular hyperplasia. Case report

Possível relação de causa-efeito entre estrogênio e hiperplasia nodular focal. Relato de caso

Ana Carolina Delazia Albuquerque Santana¹, Daniel Ferraciolli Brandão², Orlando de Castro e Silva³

ABSTRACT
A 22-year-old female patient sought medical care due to an asymptomatic solid nodule in the liver, incidentally diagnosed by abdominal ultrasound. She reported the use of an estrogen-based oral contraceptive for approximately 3 years. She denied smoking or alcohol drinking. Her mother had a history of nonalcoholic steato-hepatitis and her maternal grandmother had a hepatic hemangioma. Physical examination revealed an asymptomatic patient with discretely painful palpation of the right hypochondrium close to the xiphoid appendix. Ultrasound examination revealed a 5.9 x 4.1 cm hypoechoic nodule in the left lobule and computed tomography revealed a 5.3 x 6.3 x 4.5 cm focal lesion in the 2/3 segments. Other tests of hepatic function proved to be normal, except for serum gammaglutamyl transferase, which was increased by approximately two times the mean reference value. With a diagnosis of focal nodular hyperplasia, she was submitted to exploratory laparotomy followed by partial hepatectomy (segment III, Figure 1). With a macroscopic diagnosis of hepatic adenoma, the anatomopathological report was focal nodular hyperplasia. At present, after four years of postoperative follow-up, the patient is well and is taking progesterone instead of the estrogen-based anovulatory agent.

Key words: Liver. Focal nodular hyperplasia. Estrogen. Anovulatory. Progesterone.

Introduction
Cavernous hemangiomas, tumors of blood vessels, are the most common benign hepatic lesions. They occur as soft blue-red nodules, usually single, individualized, smaller than 2 cm, and located below Glisson’s capsule.

Focal nodular hyperplasia (FNH) mainly occurs among young women up to the third and fourth decades of life and consists of a lesion of well demarcated mass, encapsulated, usually yellow in color and lighter than surrounding hepatic tissue. A typical pattern of FNH presentation is a scar containing large arterial vessels that exhibit fibromuscular hyperplasia. This scar is depressed, central and interspersed with fibrous septa containing intense proliferation of bile ducts along its margin and an expressive lymphocyte infiltrate that irradiate towards the periphery.
Hepatic adenomas, benign hepatocyte neoplasias, also occur among young women in association with the use of estrogen-based contraceptives. They appear as pale well demarcated nodules which can be found throughout the liver parenchyma. They are bronze in color and are often colored with bile. Consisting of laminae and cell cords without expressive atypia showing variations both in size and in nucleus, they sometimes present a lighter cytoplasm due to the abundant presence of glycogen. When their location is subcapsular, they tend to rupture, usually during pregnancy, due to the action of estrogen.1

We report here the case of a patient with a hepatic nodule submitted to surgical treatment.

**Case report**

A 22-year-old female patient from Limeira, São Paulo, sought medical care due to an asymptomatic solid nodule in the liver incidentally diagnosed by abdominal ultrasound (US). She reported the use of an estrogen-based oral contraceptive for approximately 3 years. She denied smoking or alcohol drinking or the use of illicit drugs. Her mother had a history of nonalcoholic steato-hepatitis and her maternal grandmother had a hepatic hemangioma. She denied other gastrointestinal neoplasias in the family. Physical examination revealed an symptomatic patient with discretely painf ul palpation of the right hypochondrium close to the xiphoid appendix.

At admission, the patient brought a US exam in which a hypoechoic nodule was visible in the left lateral segment, measuring 5.9 x 4.1, and a computed axial tomography showing a focal lesion in the left lateral segment measuring 5.3 x 6.3 x 4.5 cm compatible with FNH but also possibly representing a hepatic adenoma (Figure 1).

Biochemical blood exams were normal, with a discrete elevation of gamma glutamyltransferase (99 U/L; normal levels: 5 to 55 U/L). Serologic tests for hepatitis B and C were negative. With a preoperative diagnosis of FNH or possible hepatic adenoma, the patient was then submitted to exploratory laparotomy and to partial hepatectomy (segment III, Figure 2) by Chevron incision.

Figure 1: Computed axial tomography with a hepatic nodule in segment 2 of the liver (arrow).
The surgical finding was a liver with a hardened lesion between segments II and III (Figure 2), with no distant lesions and with the remaining liver showing the habitual wine-colored aspect.

Anatomopathological analysis revealed macroscopically an oval, well-delimited and encapsulated lesion measuring 5.5 x 5.0 x 3.3 cm white-yellowish in color, lobulated, elastic, subcapsular and close to the raw margin of surgical resection, as can be seen in Figure 3. Histological sections revealed an encapsulated, well-delimited nodular structure filled with nodules of hepatic tissue intermingled with thick and incomplete fibrous septa, with the latter showing bile ducts as well as dilated vessels with thickened or thinned walls. The hepatocytes inside the nodules were of normal to slightly enlarged size, with the nuclei showing no atypy. The perilesional hepatic tissue exhibited preserved architecture and mild cholestasis. On this basis, a diagnosis of FNH was determined, with a resection margin close to the lesion (figures 4 and 5).
The immediate surgical evolution of the patient was good, without intercurrences; the surgical wound was dry and clean and drains, nasogastric tube and central access were removed early, with the patient being discharged from the hospital, with a free return.

The patient returned after 2 years, asymptomatic. In the subsequent year, 2010, hepatic function exams were normal and magnetic resonance imaging showed a suspicion of FNH in segment VII, which was ruled out after discussion with the radiology team. The patient was counseled to use progesterone-based contraception.

**Discussion**

FNH is the second most common benign hepatic tumor, corresponding to approximately 66 to 86% of these benign tumors. In relation to primary hepatic tumors, it corresponds to 8%, with its incidence being only lower than that of hepatic hemangiomas that affect approximately 20% of the population. In the case of hepatocellular adenomas, the incidence of these benign tumors showed an expressive increase with the introduction of contraceptives, with the current estimate being 34/100,000 women taking contra-
The risk is higher for women older than 30 years and taking high doses of estrogen-based contraceptives for more than 5 years.

The incidence of these three types of benign neoplastic lesions is higher among women. Hemangiomas are more frequent among women aged 30 to 40 years and among neonates. FNH is more prevalent among women of fertile age, i.e., 8 women: 1 man.

Another similarity among these benign lesions is that affected patients usually are asymptomatic and the tumor is detected incidentally during indirect imaging exams or at autopsy.

Symptoms that may occasionally occur are liver tumoration and pain. Pain occurs when there is rupture or hemorrhage of the nodule, a more frequent situation among women using estrogen-based oral contraceptives or during pregnancy, when women are under estrogen stimulation. Laboratory tests usually show no changes.

The influence of sex hormones such as estrogen present in oral contraceptives on the pathogenesis of hepatic adenomas has been demonstrated in the scientific literature, but their role in FNH is still debatable and has not been fully clarified. It is believed that there may be an association between the use of these contraceptives and FNH, in which the use of these agents would accelerate tumor growth. In some patients, after discontinuation of an oral contraceptive there was a spontaneous regression of FNH; however oral contraceptives do not seem to be the cause of the lesion since cases of FNH have been observed in children, men, women who never took contraceptives, and in some patients before the introduction of the hormones.

In contrast to adenomas, FNH is not a premalignant lesion. On this basis, removal of the tumor is indicated only in rare conditions such as cases of complications (rupture or hemorrhage), or when tumors are larger than 8 cm. Under other conditions, the treatment indicated for FNH is tumor embolization by arteriography or simply a conservative conduct with periodic clinical follow-up. However, since adenomas have a carcinogenic potential and a high risk of rupture, surgical treatment is the direct indication regardless of the size of the lesion. In addition, in situations of doubtful diagnosis, as in the present case, the option is for surgical treatment, as done here.

Although a relationship between the use of oral contraceptives and FNH has not been confirmed, in the present case we took into consideration the following factors:
1- The history of the development of a neoplasia
2- The fertile age of the patient, with the possibility of her getting pregnant (a risk factor for the rupture of adenomas)
3- The relation between the use of estrogen and adenomas

Thus, in the present case contraceptive therapy based on progesterone was recommended since no literature reports were found showing an association between progesterone and hepatic tumors.
Referências


8. Vecchia, C. La, Tavani A.: Female hormones and benign liver tumours. Digestive and Liver Disease (38) 2006; 535-6